Fine-tuning of frontline tyrosine kinase inhibitor (TKI) therapy in chronic-phase chronic myeloid leukemia: The choice of the right TKI for the right patient

Nuhoğlu Kantarcı E., Tolgay E., EŞKAZAN A. E.

Cancer, vol.129, no.17, pp.2610-2612, 2023 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Editorial Material
  • Volume: 129 Issue: 17
  • Publication Date: 2023
  • Doi Number: 10.1002/cncr.34938
  • Journal Name: Cancer
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, Abstracts in Social Gerontology, BIOSIS, CAB Abstracts, CINAHL, EMBASE, MEDLINE, Public Affairs Index, Veterinary Science Database
  • Page Numbers: pp.2610-2612
  • Bursa Uludag University Affiliated: Yes

Abstract

In an era when tyrosine kinase inhibitors are gaining acceptance in the treatment scene of chronic-phase chronic myeloid leukemia, this editorial focuses on the search for the optimal patient-based frontline treatment option while evaluating a recent study by Tiribelli and colleagues, which is published in this issue of Cancer.